Workup and Treatment for a 59-Year-Old Man with Interstitial Lung Disease
For a 59-year-old man with ILD, immediately obtain high-resolution chest CT (HRCT), pulmonary function tests (PFT including spirometry, total lung capacity, and DLCO), and comprehensive autoimmune serological workup to determine the specific ILD subtype, as treatment differs dramatically based on whether this is idiopathic pulmonary fibrosis, connective tissue disease-associated ILD, or another etiology 1, 2, 3.
Initial Diagnostic Workup
Imaging
- HRCT is the primary diagnostic tool - look specifically for:
Pulmonary Function Testing
- Spirometry with FVC measurement - a 5% decline over 12 months doubles mortality risk 3
- Total lung capacity (TLC) - confirms restrictive pattern
- DLCO measurement - any value below lower limit of normal attributed to ILD is significant 2, 4
- Baseline 6-minute walk test with oxygen saturation monitoring - desaturation below 88% indicates need for supplemental oxygen 3
Laboratory Evaluation
For CTD-ILD screening, obtain:
- Rheumatoid factor (RF) and anti-CCP antibodies (for RA-ILD)
- ANA, anti-Scl-70/anti-topoisomerase (for systemic sclerosis)
- Anti-Jo-1 and myositis panel (for inflammatory myopathy)
- Anti-Ro/La (for Sjögren's syndrome)
- Complete metabolic panel and inflammatory markers 2
Clinical Assessment
- Auscultate for fine Velcro crackles - moderate sensitivity for early ILD 2
- Assess for extrapulmonary CTD manifestations: skin changes, joint involvement, Raynaud's phenomenon, muscle weakness
- Quantify dyspnea and cough - though 90% of RA-ILD patients may lack these symptoms initially 2
Risk Stratification
High-Risk Features Requiring Aggressive Monitoring
- Male gender with smoking history
- Baseline FVC <70% or DLCO significantly reduced
- UIP pattern on HRCT (associated with poor prognosis, especially in RA-ILD) 2
Progressive Pulmonary Fibrosis Criteria
Diagnose PPF if ≥2 of the following occur within past year:
- Worsening respiratory symptoms
- Physiological progression (FVC or DLCO decline)
- Radiological evidence of progression on CT 2
Treatment Algorithm
If Connective Tissue Disease-Associated ILD is Identified
For Systemic Sclerosis-ILD:
- First-line: Mycophenolate mofetil (preferred over other options) 1, 5
- Alternative: Tocilizumab or cyclophosphamide 1, 5
- Conditionally add nintedanib if progressive despite immunosuppression 1
- Strongly avoid glucocorticoids - particularly dangerous in SSc-ILD due to renal crisis risk 1, 5
For Rheumatoid Arthritis-ILD:
- First-line: Mycophenolate mofetil 1, 5
- Alternatives: Azathioprine, rituximab, or cyclophosphamide 1, 5
- Short-term glucocorticoids only (≤3 months) 5
- For progressive RA-ILD despite first-line therapy: Add nintedanib or pirfenidone 1, 2
- Evaluate the balance between inflammatory vs fibrotic process to guide anti-inflammatory vs antifibrotic therapy 2
For Inflammatory Myopathy-ILD:
- First-line: Mycophenolate mofetil 1, 5
- Conditionally recommend JAK inhibitors or calcineurin inhibitors as first-line options 1, 5, 1
- Alternatives: Azathioprine, rituximab 1
- Short-term glucocorticoids acceptable 5
For Mixed Connective Tissue Disease-ILD:
- First-line: Mycophenolate mofetil 1, 5
- Alternatives: Azathioprine, tocilizumab 1, 5
- Caution with glucocorticoids if SSc phenotype present (renal crisis risk) 5
If Idiopathic Pulmonary Fibrosis
First-line antifibrotic therapy: Nintedanib or pirfenidone - both slow FVC decline by 44-57% annually 3, 6
Avoid These Medications
- Leflunomide - can cause or worsen ILD 1
- Methotrexate - stop if ILD develops while on it, though can continue for extrapulmonary disease if ILD stable 1
- TNF inhibitors - observational data suggest harm or no benefit for ILD 1
Monitoring Protocol
Initial 3-6 Months
- Repeat PFTs within 3 months to establish rate of progression 2
- Repeat HRCT within 6 months to assess response and detect progression 2
Ongoing Surveillance
For mild ILD (FVC ≥70%, <20% fibrosis on HRCT):
- PFTs every 6 months for first 1-2 years 2
For moderate-severe ILD or progressive disease:
Multidisciplinary Team Approach
Mandatory involvement of:
- Pulmonologist
- Rheumatologist (if CTD suspected/confirmed)
- Thoracic radiologist for HRCT interpretation
- Consider pathologist if biopsy needed (though bronchoscopy and surgical lung biopsy are NOT routinely recommended for CTD-ILD diagnosis) 2
This multidisciplinary discussion improves diagnostic accuracy and outcomes, particularly for complex cases 2.
Supportive Care
- Supplemental oxygen if desaturation <88% on 6-minute walk test - improves quality of life 3
- Structured pulmonary rehabilitation - reduces symptoms and improves 6-minute walk distance 3, 6
- Screen for pulmonary hypertension - develops in up to 85% of end-stage fibrotic ILD; consider inhaled treprostinil if present 3
Lung Transplant Referral
Refer early for evaluation if:
- Progressive disease despite optimal medical management
- Advanced ILD with declining function
- Median post-transplant survival is 5.2-6.7 years vs <2 years for advanced ILD without transplant 3
- For SSc-ILD with progression: Conditionally recommend referral for stem cell and/or lung transplantation 5, 1
Critical Pitfalls to Avoid
- Do not delay HRCT - chest radiography has minimal value 2
- Do not assume absence of dyspnea excludes ILD - 90% of RA-ILD patients lack respiratory symptoms initially 2
- Do not use glucocorticoids as monotherapy for SSc-ILD - strongly contraindicated 1, 5
- Do not add antifibrotics to stable mycophenolate therapy - conditionally recommended against 1
- Do not stop DMARDs solely due to theoretical lung toxicity concerns - benefit/risk ratio favors continuation with careful monitoring 2